（原标题：专访中国英国商会主席：英企对华信心日趋乐观，三成计划扩大投资） 南方财经21世纪经济报道记者郑青亭 北京报道 "目前，约三分之一的受访企业计划扩大投资，略超40%的企业保持现状，仅有极少数考虑缩减。市场 规模与完善的基础设施是重要支撑。更重要的是，在全球充满不确定性的环境下，中国展现出更强的可 预测性与稳定性，这对英国企业极具吸引力。" 中国英国商会主席陶克瑞(Chris Torrens)在北京接受21世 纪经济报道记者专访时说道。 12月9日，中国英国商会正式发布《在华英国企业：2025-26年度商业信心调查报告》（以下简称报 告）。报告表明，英国企业总体对其在中国市场的前景日趋乐观，多个重点行业认为明年有望成为疫情 以来业务表现最为强劲的一年。 陶克瑞表示，"这种积极态势与英国对华坚持务实合作的政策密不可分。今年以来，两国重启经济财金 对话，经贸联委会等重要政府间合作机制，为解决市场准入等议题提供了更加稳定、透明的沟通框 架。" 本次调查报告共收录超过300家在中国大陆运营的英国企业的观点与预期。报告显示，英国在华企业全 年营收预期较去年小幅回升，38%的企业预计2025年收入将高于2024年， ...

Core Insights - 2025 is a pivotal year for China's pharmaceutical sector, marked by the implementation of policies aimed at enhancing service quality and accessibility, as well as the transition from the "14th Five-Year Plan" to the "15th Five-Year Plan" [1][2] Group 1: Healthcare System Improvements - Over 90% of township health centers and community health service centers have met basic service capability standards, with many reaching recommended standards [1] - The inclusion of the HPV vaccine in the national immunization program enhances public health protection [1][5] - The proportion of diagnoses from grassroots medical institutions has remained above 50% since the "14th Five-Year Plan" began, indicating a significant role in healthcare delivery [4] Group 2: Medical Insurance and Procurement Reforms - The 11th batch of national drug procurement included 55 drugs across various therapeutic areas, with a focus on maintaining clinical stability and quality [6][9] - The national medical insurance bureau is advancing direct settlements with pharmaceutical companies and optimizing procurement measures to ensure quality and supply [7][9] - The introduction of a commercial insurance directory for innovative drugs marks a significant step in expanding healthcare coverage [11][12] Group 3: Support for Pharmaceutical Innovation - The government has introduced measures to support the development of innovative drugs, including financial backing and streamlined approval processes [10][11] - Approximately 80% of innovative drugs are expected to be included in the medical insurance directory within two years of their market launch [11] - The launch of the drug price registration system aims to facilitate a global pricing strategy for pharmaceutical companies, enhancing their market competitiveness [12]

Core Insights - The article highlights the transformative role of commercial health insurance in addressing healthcare disparities and reducing patient burdens, particularly in the context of the "Healthy China 2030" strategy and ongoing healthcare reforms [1][2] Group 1: Regulatory Guidance and Market Needs - The development of high-quality health insurance is significantly influenced by regulatory policies aimed at expanding coverage and enriching product offerings for patients with pre-existing conditions [2] - Traditional insurance products primarily focus on healthy individuals, but nearly 40% of the population has health issues, indicating a gap in coverage for patients with chronic diseases and tumors [2][3] Group 2: Product Innovation - In response to rising breast cancer rates, the company launched the "Pink Guardian" insurance product in 2022, providing specialized coverage for post-operative patients and filling a market gap for patients with pre-existing conditions [3] - The "Pink Guardian" product has undergone six iterations by March 2025, now covering all 58 domestic innovative breast cancer drugs with a reimbursement rate of 100% [3] Group 3: Service Integration - The company emphasizes a shift from traditional compensation models to an "insurance + service" approach, addressing gaps in disease prevention, treatment assistance, and rehabilitation [4] - A comprehensive health management solution is provided, including basic health management and high-end medical services, to meet diverse consumer health needs [4][5] Group 4: Payment and Service Model - The "payment + service" model is identified as a key innovation in health insurance, reflecting a shift in consumer expectations from merely financial risk coverage to seeking quality medical service solutions [6][7] - The company has developed a disease management system that utilizes data and technology to provide proactive health management services throughout the healthcare continuum [7][8] Group 5: Ecosystem Collaboration - The integration of health insurance with the pharmaceutical industry is crucial for achieving the goal of "protecting people's health," necessitating collaboration across various sectors [9] - The company has established a health protection ecosystem that links insurance payments, medical services, and pharmaceutical supply, facilitating mutual benefits and collaborative development [9][10]

近日,在澳门威尼斯人金光会展中心举办的"全球智能机械与电子产品博览会"创新科技成果发布会上,中国医学装备协会健康 空间装备与技术分会会长、玄域(北京)等离子体科技发展有限公司董事长戴玮霆先生,与LGT皇家银行亚太区负责人吴菲云 女士,分别代表双方机构正式签署战略投资合作协议。本次签约标志着以"健康空间场景化"为核心的前沿产业领域,成功引入 了重要的国际战略资本,开启了"科技-产业-金融"良性循环的新篇章,为健康空间事业注入强劲动能。 强强联合:国际金融资本赋能尖端科技企业 本次签约投资方LGT皇家银行是全球领先的私人银行与投资集团,以其悠久的历史、稳健的资产管理能力和卓越的国际视野 著称。此次对"健康空间"项目的战略性投资,体现了国际顶级金融机构对以科技创新驱动健康空间产业升级这一赛道的深刻 认同与长远信心。 紧扣国家战略,定义产业未来 此次战略签约,具有多层次的深远意义: 践行"健康中国2030"战略:健康空间"治空间未病",从根源解决病态空间,提升全民健康水平。 呼应"十五五"规划方向:"健康空间"是典型的新质生产力代表。此次金融资本的注入,将有力推动相关技术研发与装备制造 的"再工业化"升级。 展望未来 ...

Core Insights - The National Healthcare Security Administration has officially announced the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, adding 114 new drugs, bringing the total to 3,253, covering various treatment areas including cancer, chronic diseases, and rare diseases [1][2] Group 1: Drug Inclusion and Coverage - The updated catalog includes multiple new blood cancer drugs, such as Maleate Acalabrutinib Tablets, which are significant for patients with chronic lymphocytic leukemia and other blood cancers [1] - The inclusion of Maleate Acalabrutinib Tablets for CLL/SLLL marks a comprehensive coverage for various stages of blood cancer treatment, addressing previously unmet needs [2] Group 2: Impact on Patients and Healthcare - The update enhances clinical treatment options for blood cancer patients, filling gaps in the treatment of chronic lymphocytic leukemia and supporting the goal of improving cancer survival rates as part of the "Healthy China 2030" initiative [2] - The new drug additions are expected to alleviate the economic burden on patients and provide more accessible medication support for clinical treatment [2]

Group 1 - The core message of the article emphasizes the importance of the "Healthy China 2030" initiative, aiming for a national average life expectancy of 79 years and a 15% increase in the five-year cancer survival rate by 2030 [1][2] - The "Healthy China 2030" plan is closely linked to the 14th Five-Year Plan, marking the period from 2026 to 2030 as crucial for achieving the health goals set forth in the initiative [1] - The initiative highlights the need for a dual approach of "healthy living + proactive screening" to achieve its targets, focusing on community engagement and lifestyle changes [2] Group 2 - The rising incidence of colorectal cancer in China, with over 510,000 new cases reported in 2022, underscores the urgency for early screening and intervention [2] - The government has included eight types of cancer in free screening programs, significantly increasing access to preventive services for the public [2] - The article stresses that achieving the health goals by 2030 relies more on community health initiatives and lifestyle changes than on hospital treatments [2]

Core Insights - The article highlights the significant wealth creation capability of China's pharmaceutical industry, exemplified by the rise of the new female billionaire, Zhong Huijuan, and her daughter, with a wealth of 141 billion yuan, marking a historic shift from imitation to innovation in the sector [5][9][10]. Group 1: Pharmaceutical Industry Transformation - The development trajectory of Hansoh Pharmaceutical illustrates the industry's transition from a "copycat" strategy to a robust innovation-driven model, supported by a comprehensive R&D network across multiple regions [5][10]. - The Chinese pharmaceutical industry has evolved from a state-controlled system to a competitive market, achieving a remarkable increase in production value from 73 million yuan in 1978 to 131.7 billion yuan in 1998, reflecting an 18-fold growth over 20 years [13][14]. - The launch of the "Major New Drug Creation" initiative in 2008 marked a pivotal shift towards innovation, resulting in over 75 new drug approvals since its inception, significantly enhancing the industry's global competitiveness [14][15]. Group 2: Financial Performance and Market Dynamics - The total wealth of the top 50 female entrepreneurs in China reached 1.9 trillion yuan, a 32% increase from the previous year, indicating a growing trend in wealth accumulation within the sector [9]. - The domestic innovative drug market reached a scale of 122.6 billion yuan in 2023, becoming a key driver of growth for the pharmaceutical industry, with a notable increase in the number of innovative medical devices approved [15][18]. - Hansoh Pharmaceutical's core product, Amivantamab, generated over 3 billion yuan in revenue in 2023 and became the first Chinese original EGFR-TKI to be approved for sale in the UK, marking a significant milestone for the company [10][11]. Group 3: Future Outlook and Strategic Directions - The future of China's pharmaceutical industry is poised for a qualitative leap, driven by policy guidance, technological integration, and global market restructuring, with a focus on original innovation and global collaboration [18][19]. - The industry is expected to transition from a model of "imitation and innovation" to one centered on "original innovation" and "global competition," necessitating the establishment of proprietary barriers in technology and patenting [19][20]. - The integration of artificial intelligence in drug development is anticipated to revolutionize the industry, significantly reducing the time required for drug discovery and production processes [18][19].

Core Viewpoint - Beijing Tongrentang Co., Ltd. is implementing a core strategy of "inheriting essence and innovating with integrity," focusing on cultural empowerment, digital intelligence, professional collaboration, and quality foundation in its marketing approach [1][2]. Group 1: Cultural Empowerment - The company is breaking traditional cultural dissemination models by creating a "Traditional Chinese Medicine Health Culture IP" centered around the "Qingxin Jiannao Huoluo Exercise," which aims to establish a closed-loop operation of "cultural awareness - user education - product scenario binding" [4]. - This initiative targets the elderly population, providing practical "preventive healthcare" solutions through a platform that covers 14 core cities and nearly 2 million elderly families [4]. - Collaborations with organizations like the China Marriage and Family Research Association and the China Elderly Sports Association enhance community engagement and service offerings [4]. Group 2: Digital Intelligence - The company is accelerating its digital transformation to enhance operational efficiency and user service, establishing a "data-driven, intelligent collaboration" marketing model [6]. - A digital marketing decision-making platform has been developed to collect data across various dimensions, enabling real-time market trend analysis and dynamic optimization of marketing strategies [6]. - The launch of an AI-driven health service platform in collaboration with Xiaomi aims to lower barriers for users seeking TCM services and effectively reach younger consumers [7]. Group 3: Professional Collaboration - The company is focusing on grassroots medical services as a key area for market expansion, creating a collaborative ecosystem among enterprises, medical institutions, and grassroots practitioners [8]. - The "Strong Foundation Cultivation of Chinese and Western Medicine" project aims to ensure high-quality training for practitioners through a structured selection and training process [8][9]. Group 4: Quality Foundation - Quality is emphasized as the lifeline of the brand, with a comprehensive supply chain quality control system established from sourcing to production and end-user traceability [10]. - The company adheres to strict standards in sourcing, particularly with its Jilin ginseng, which has received multiple organic certifications, ensuring high-quality products [10]. - A traceability system allows consumers to access detailed information about the entire process of herbal medicine, reinforcing trust in the brand's quality [10].

Core Insights - The "Vitality Plan" project, initiated by Tencent SSV Health Inclusive Laboratory, China Family Newspaper, and Social Value Investment Alliance (Shenzhen), has concluded its first phase after over two years of development, aligning with the "Healthy China 2030" initiative [1] Group 1: Project Overview - The "Vitality Plan" has screened over 170,000 individuals, reaching an audience of more than 170,000 people, with collaboration from 275 partner organizations [1] - The project has effectively improved daily screening efficiency for breast cancer and accuracy in congenital heart disease detection [1] - Beneficial explorations have been made in areas such as prenatal psychological intervention for pregnant women and prevention of dental diseases in children [1] Group 2: Project Awards - Four "Health Inclusive Foundation Projects" were selected, including initiatives focused on children's oral health, AI-assisted breast cancer screening in low-resource areas, and comprehensive prevention of limb development defects [2] - Four "Health Digital Innovation Projects" were recognized, featuring studies on social psychological support for pregnant women, integrated mental health service models, and smart systems for congenital structural deformities [2] - Four "Social Value Pioneer Projects" were awarded, highlighting AI-assisted initiatives for hearing-impaired women, early public screening for viral retinitis, and the establishment of a digital platform for pediatric allergic diseases [2] - Five "Sustainable Maternal and Child Health Projects" were acknowledged, including digital health management for perinatal depression and AI-assisted screening for congenital heart disease [2]

Group 1: Technology Engine - The core driving forces of industry upgrades are artificial intelligence, big data, and cloud computing, which are penetrating various sectors from smart manufacturing to public services [2] - There is a growing demand for high-end digital technology talent, particularly in fields such as AI, computer science, data science, cybersecurity, and IoT [2] Group 2: New Energy and Low-Carbon Environmental Protection - The "dual carbon" goals (peak carbon emissions by 2030 and carbon neutrality by 2060) are reshaping China's energy structure and industrial logic [3] - The transition to new energy sources, low-carbon technology development, and circular economy are becoming inevitable trends, supported by strong policies and expanding market demand [3] - Employment opportunities are emerging across energy production, engineering construction, and environmental governance [3] Group 3: Biomedicine and Health Sciences - The "Healthy China 2030" strategy is driving rapid development in fields such as precision medicine, genetic technology, and biopharmaceuticals [5] - Professionals with both research capabilities and practical experience will be the core competitive force in the healthcare industry [5] - Recommended fields include biomedical engineering, biotechnology, public health, and health management [5] Group 4: Intelligent Manufacturing and Industrial Internet - The essence of Industry 4.0 is to inject "soul" into manufacturing, leading to the inevitable transformation towards intelligent and digital manufacturing [6] - There is a significant talent gap in fields such as intelligent manufacturing engineering, industrial engineering, and robotics [6] Group 5: Modern Agriculture and Smart Agriculture - The rural revitalization strategy is promoting the transition from traditional agriculture to smart production [8] - Areas such as agricultural information technology and rural e-commerce present substantial potential for graduates [8] - Recommended fields include smart agriculture, agricultural information technology, and agricultural economics [8] Group 6: Cross-Disciplinary and Composite Professions - The future demand is for "bridge-type" talents who can integrate technology with industry, rather than single-domain experts [9] - Emerging interdisciplinary fields include AI in medicine, new energy materials, fintech, and pollution control technology [9] Group 7: Practical Tips for Choosing Schools and Majors - Interest is highlighted as the best teacher, emphasizing the importance of choosing fields that are not only promising but also enjoyable [11] - Mastery of foundational subjects like mathematics and physics is crucial for future adaptability in various popular majors [11] - Attention should be given to universities with unique disciplines, especially non-elite institutions in specific niches that offer high-quality employment resources [11]